ACTA1 and colorectal carcinoma: Finally, we found reduced levels of fibrosis in CRC metastatic lesions from lorlatinib-treated mice, as seen by both decreased collagen deposition and reduced numbers of αSMA+ fibroblasts, compared with metastatic lesions from vehicle-treated mice (Fig. 2n, o).